elacestrant + palbociclib

Elacestrant + palbociclib is an **investigational oral combination therapy** used in clinical studies for the treatment of **estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer**. - **Elacestrant** is a selective estrogen receptor degrader (SERD) that binds, inhibits, and promotes degradation of the estrogen receptor, leading to suppression of estrogen-dependent signaling in tumor cells. - **Palbociclib** is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that blocks CDK4/6-mediated phosphorylation of the retinoblastoma protein (Rb), causing cell cycle arrest at the G1 phase. The combination aims to improve efficacy in cancers resistant to endocrine therapy by **targeting both the estrogen signaling pathway and cell cycle progression**. Tested in the ELEVATE (NCT05563220) trial, this combination remains under clinical investigation and is not approved for standard therapy use[1][3][5][7].